Treatment Resistant Depression Clinical Trial
Official title:
Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic
Repetitive Transcranial Magnetic Stimulation (rTMS) using intermittent theta burst stimulation (iTBS) has been found to be a non inferior protocol to standard rTMS for the treatment of major depressive disorder. An accelerated course is of particular interest given the safety profile of the procedure and the potential to treat people more quickly making the treatment more accessible. This study aims to assess the feasibility and clinical outcomes of a high dose iTBS protocol in patients with depression in the context of unipolar or bipolar II disorder who are waiting for Electroconvulsive therapy (ECT) or rTMS due to degree of treatment resistance or severity of symptoms. This is a prospective, open-label, interventional pilot study wherein patients who have been diagnosed with major depressive disorder and referred to brain stimulation clinic, will be recruited for the treatment. Patients will be administered eight questionnaires before and after the treatment to assess the change in clinical outcomes.
Participants will receive same stimulation protocol, however they will be given 6 times per day instead of once per day. Each Treatment will consist of a single iTBS treatment delivering 600 puses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duy cycle of 2 seconds on, 8 seconds off, over 60 cycles and it takes about 3 minutes at a target of 90 to 120% of the subject's resting motor threshold. Treatment will be given through the device that is usually used, which is Magpro by Magventure, B70 Fluid-Cooled Coil . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
| Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
| Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
| Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
| Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
| Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
| Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
| Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
| Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
| Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
| Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
| Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
| Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
| Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
| Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
| Active, not recruiting |
NCT04451135 -
CET- REM (Correlating ECT Response to EEG Markers)
|
N/A | |
| Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
| Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
| Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
| Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 |